𝔖 Bobbio Scriptorium
✦   LIBER   ✦

The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function

✍ Scribed by Meletios Dimopoulos; Adrian Alegre; Edward A. Stadtmauer; Hartmut Goldschmidt; Jeffrey A. Zonder; Carlos M. de Castro; Zvenyslava Masliak; Donna Reece; Marta Olesnyckyj; Zhinuan Yu; Donna M. Weber

Publisher
John Wiley and Sons
Year
2010
Tongue
English
Weight
199 KB
Volume
116
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

The combination of intermediate doses of
The combination of intermediate doses of thalidomide and dexamethasone reduces bone marrow micro-vessel density but not serum levels of angiogenic cytokines in patients with refractory/relapsed multiple myeloma
✍ E. Hatjiharissi; E. Terpos; M. Papaioannou; C. Hatjileontis; V. Kaloutsi; G. Gal πŸ“‚ Article πŸ“… 2004 πŸ› John Wiley and Sons 🌐 English βš– 288 KB

## Abstract The aim of the study was the evaluation of anti‐angiogenic activity of the combination of intermediate doses of thalidomide and dexamethasone in patients with refractory/relapsed myeloma. Twenty‐five patients were included in the study. Microvessel density (MVD) was evaluated in marrow

Long-term efficacy and safety of zoledro
Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma : A randomized, double-blind, multicenter, comparative trial
✍ Lee S. Rosen; David Gordon; Mary Kaminski; Anthony Howell; Andrew Belch; John Ma πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 151 KB πŸ‘ 2 views

## Abstract ## BACKGROUND The goal of the current study was to compare the long‐term (25‐month) safety and efficacy of zoledronic acid with pamidronate in patients with bone lesions secondary to advanced breast carcinoma or multiple myeloma. ## METHODS Patients (__n__ = 1648) were randomized to